CSL brings Se­qirus, Vi­for un­der par­ent um­brel­la brand in iden­ti­ty re­vamp

12 Aug 2022
endpts.com
CSL is gath­er­ing its brands un­der the fam­i­ly name um­brel­la, re­nam­ing its vac­cine and new­ly ac­quired nephrol­o­gy spe­cial­ty busi­ness­es with the par­ent ini­tials.
Cred­it: CSL
CSL brings Se­qirus, Vi­for un­der par­ent um­brel­la brand in iden­ti­ty re­vamp
Preview
Source: Endpts
Click on the im­age to see the full-sized ver­sion
CSL brings Se­qirus, Vi­for un­der par­ent um­brel­la brand in iden­ti­ty re­vamp
Preview
Source: Endpts
An­tho­ny Fa­ri­na
CSL Se­qirus and CSL Vi­for join CSL Plas­ma and CSL Behring as the four now uni­form­ly brand­ed busi­ness units of the glob­al bio­phar­ma. The Se­qirus vac­cine di­vi­sion was formed in 2015 with the com­bi­na­tion of bioC­SL and its pur­chase of No­var­tis’ flu vac­cine busi­ness. CSL picked up Vi­for Phar­ma late last year in an $11.7 bil­lion deal for the nephrol­o­gy, iron de­fi­cien­cy and car­dio-re­nal drug de­vel­op­er.
“The tim­ing is right to bring all the busi­ness units to­geth­er un­der CSL, lever­ag­ing the CSL iden­ti­ty and build­ing an aligned, sin­gle strat­e­gy and sin­gle pur­pose com­pa­ny,” An­tho­ny Fa­ri­na, CSL chief cor­po­rate af­fairs and com­mu­ni­ca­tions of­fi­cer, said in an email in­ter­view. He added that the new Vi­for ac­qui­si­tion and in­te­gra­tion “gave us the unique op­por­tu­ni­ty to take a broad­er look at the CSL brand and how it has evolved.”
CSL brings Se­qirus, Vi­for un­der par­ent um­brel­la brand in iden­ti­ty re­vamp
Preview
Source: Endpts
Paul Per­reault CSL
CSL first be­gan ex­plor­ing a brand re­fresh in 2021, he said, and plans to launch a dig­i­tal-fo­cused ad cam­paign in Sep­tem­ber and run­ning in­to 2023 to launch the new glob­al iden­ti­ty.
Paul Per­reault, CEO and man­ag­ing di­rec­tor, re­ferred to the com­ing to­geth­er as “a co­he­sive red thread that runs through all things CSL.”
The CSL ini­tials at the be­gin­ning of each busi­ness name sig­ni­fy “that we are now one uni­fied com­pa­ny – one pur­pose, one set of val­ues, one strat­e­gy, one DNA and one iden­ti­ty.”
CSL em­ploys 30,000 peo­ple in 100 coun­tries, with cor­po­rate head­quar­ters in Mel­bourne, Aus­tralia.
CSL Plas­ma is one of the largest plas­ma col­lec­tion net­works in the world and CSL Behring de­vel­ops ther­a­pies for rare dis­eases in hema­tol­ogy, im­munol­o­gy and res­pi­ra­to­ry. Its lead­ing prod­ucts in­clude Idelvion for he­mo­phil­ia B, Kcen­tra co­ag­u­lant to coun­ter­act blood-thin­ning drugs such as war­farin, and Hae­gar­da to treat peo­ple with Hered­i­tary An­gioede­ma (HAE).
2021 fis­cal year sales (end­ed June 2021) tal­lied $10 bil­lion, boost­ed by Se­qirus’ 30% rev­enue growth on a record vol­ume of flu vac­cines. CSL will re­port 2022 fis­cal full-year sales on Au­gust 17.
CSL Behring teams with fa­mous pho­tog­ra­ph­er to fo­cus on he­mo­phil­ia for art ex­hib­it and on­line gallery cam­paign
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.